HER2(+) Breast Cancer Previously Treated with T-DM1
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

HER2(+) Breast Cancer Previously Treated with T-DM1

Sponsor: Daiichi Sankyo, Inc.

Protocol DS8201-A-U201: A phase 2 trial of DS-8201a, an antibody-drug conjugate, that will be administered intravenously as a monotherapy for patients with HER2 positive, unresectable or metastatic breast cancer that has previously been treated with T-DM1.